Qiagen Exceeds Third-Quarter Earnings and Revenue Projections

5aef9d2c3a1197e2da90245db0f230e1 2 Qiagen Exceeds Third-Quarter Earnings and Revenue Projections

Qiagen N.V. (NYSE:QGEN) has announced its financial results for the third quarter, reporting earnings of $0.65 per share. This figure surpasses the Zacks Consensus Estimate of $0.63 per share and represents a slight increase from the $0.64 per share reported in the same quarter last year. These earnings are adjusted for non-recurring items, highlighting a positive earnings surprise of 3.18% for the quarter.

In the preceding quarter, Qiagen was expected to report earnings of $0.60 per share but delivered $0.62, resulting in a 3.33% surprise. Over the past four quarters, Qiagen has exceeded consensus earnings per share (EPS) estimates three times, demonstrating a consistent pattern of outperformance. This trend indicates the company’s ability to manage expectations and deliver better-than-anticipated financial results.

For the quarter ending in September 2026, Qiagen reported revenues of $547.87 million, which exceeded the Zacks Consensus Estimate by 1.56%. This is an increase from the $532.58 million in revenues reported in the same period last year. Like its EPS performance, Qiagen has surpassed revenue estimates in three of the last four quarters. This consistent revenue growth underscores the company’s robust operational capabilities and its ability to capture market opportunities effectively.

The immediate impact on Qiagen’s stock price will likely depend on the management’s commentary during the earnings call and future earnings expectations. Since the beginning of the year, Qiagen shares have increased by approximately 6.4%, compared to the S&P 500’s gain of 10.6%. While the company’s stock has underperformed the broader market, its positive earnings report may influence future stock movements.

Looking Ahead for Qiagen

Despite underperforming the broader market this year, investors are keen to understand what lies ahead for Qiagen. A critical factor in determining the stock’s future performance is its earnings outlook, which includes current consensus expectations for upcoming quarters and any recent changes to these forecasts. Investors often look at earnings revisions as a key indicator of a company’s future performance.

Empirical evidence suggests a strong link between short-term stock movements and trends in earnings estimate revisions. Investors can monitor these revisions independently or use tools like the Zacks Rank, which effectively leverages earnings estimate revisions. Prior to this earnings announcement, Qiagen’s estimate revisions trend was favorable, resulting in a Zacks Rank #2 (Buy). This suggests that Qiagen shares are expected to outperform the market in the near term.

As the company has just released its latest earnings report, it will be interesting to observe how estimates for upcoming quarters and the current fiscal year evolve. The current consensus EPS estimate stands at $0.65 on $573.42 million in revenues for the next quarter and $2.44 on $2.14 billion in revenues for the fiscal year. These projections will be closely watched by investors as they assess Qiagen’s growth trajectory.

Investors should also consider the broader industry outlook, as it can significantly influence stock performance. The Medical – Biomedical and Genetics industry, to which Qiagen belongs, currently ranks in the top 45% of over 250 Zacks industries. Research indicates that industries in the top 50% generally outperform those in the bottom 50% by more than a 2-to-1 margin. This industry ranking suggests a favorable environment for Qiagen’s continued growth.

Another company in the same industry, CytomX Therapeutics (NASDAQ:CTMX), is set to release its results for the quarter ending September 2026 on November 5. CytomX is expected to report a quarterly loss of $0.09 per share, consistent with the previous year. The consensus EPS estimate for CytomX has remained unchanged over the last 30 days. Additionally, CytomX’s revenues are projected to be $4.19 million, a decrease of 29.8% from the year-ago quarter. This comparison provides context for Qiagen’s performance within the industry.

For those interested in further analysis, Zacks Investment Research offers reports on both Qiagen and CytomX Therapeutics, providing insights into their financial performance and market expectations. These reports can be valuable resources for investors looking to make informed decisions based on comprehensive data and analysis.

Footnotes:

  • Qiagen reported third-quarter earnings of $0.65 per share, beating estimates. Source.
  • Qiagen’s quarterly revenues were $547.87 million, exceeding expectations. Source.
  • CytomX Therapeutics is expected to report a quarterly loss of $0.09 per share. Source.

Source

Featured Image: Megapixl @ Rmarmion

Disclaimer